Menu

Pipeline Overview*

PRODUCT2 Indication Pre-clinical Phase 1/2 Phase 3 Commercial1
Talicia® H. pylori infection3
APPROVED BY U.S. FDA NOVEMBER 2019
Aemcolo® Travelers' Diarrhea4
U.S. EXCLUSIVE LICENSE
Donnatal® IBS and acute enterocolitis5
U.S. CO-PROMOTION
Mytesi® Non-infectious diarrhea in HIV/AIDS patients6
U.S. CO-PROMOTION
EnteraGam® Chronic diarrhea and loose stools7
U.S. EXCLUSIVE LICENSE
Esomeprazole Strontium DR Capsules GERD and other GI conditions6
U.S. COMMERCIALIZATION LICENSE
RHB-104 Crohn's disease
RHB-204 NTM infections
RHB-102
(Bekinda®)		 Gastroenteritis & gastritis
IBS-D
RHB-106 Bowel cleanser
ABC294640
(Yeliva®)		 Multiple indications
RHB-107 Oncology/GI
Other
 RIZAPORT®
(RHB-103)		 Migraine
* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies ;
1 Aemcolo® planned to be launch in Q4/19; Talicia planned to be launched in Q1/2020
2Bekinda® (RHB-102) and Yeliva® (ABC294640) are proposed tradenames which are subject to FDA review and approval
3Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: here
4 Aemcolo® (Rifamycin) is indicated for the treatment of Travelers’ Diarrhea caused by non-invasive strains of Escherichia coli in adults. For full prescribing information see: www.aemcolo.com
5 Donnatal® (Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide), a prescription drug, is classified as possibly effective as an adjunctive therapy in the treatment of irritable bowel syndrome and acute enterocolitis. For full prescribing information see: www.Donnatal.com
6 Mytesi® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). For full prescribing information see: www.Mytesi.com
7 EnteraGam® (serum-derived bovine immunoglobulin/protein isolate, SBI) is a medical food which must be administered under medical supervision

Company Profile

RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company primarily focused on development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases.

Read more

Recent News

SEE ALL NEWS
Home | Site Map
Copyright © 2017 RedHill. All Rights Reserved. Created by Catom web design | SEO
Thank you for visiting RedHill's website at www.redhillbio.com ("RedHill Site"). By clicking "OK", you acknowledge and understand that you will be linked outside of the RedHill Site and into other independent third party websites ("Third Party Sites"). You further acknowledge and agree that we have no control over the Third Party Sites nor over any content contained therein. You further acknowledge that we are not responsible in any way for the availability, suitability, accuracy and completeness of any information or links contained in any of the Third Party Sites, nor do we endorse, or are we responsible or liable for, any services, content, advertisements, products or any materials on, or available from or through, any of the Third Party Sites. In addition, we urge you to carefully review each of the Third Party Sites' terms of service and privacy policies, if such exist, before visiting such Third Party Sites. Ok
Thank you for visiting RedHill's website at www.redhillbio.com ("RedHill Site"). By clicking "OK", you acknowledge and understand that you will be linked outside of the RedHill Site and into other independent third party websites ("Third Party Sites"). You further acknowledge and agree that we have no control over the Third Party Sites nor over any content contained therein. You further acknowledge that we are not responsible in any way for the availability, suitability, accuracy and completeness of any information or links contained in any of the Third Party Sites, nor do we endorse, or are we responsible or liable for, any services, content, advertisements, products or any materials on, or available from or through, any of the Third Party Sites. In addition, we urge you to carefully review each of the Third Party Sites' terms of service and privacy policies, if such exist, before visiting such Third Party Sites. Ok